JP2022525704A5 - - Google Patents
Info
- Publication number
- JP2022525704A5 JP2022525704A5 JP2022504337A JP2022504337A JP2022525704A5 JP 2022525704 A5 JP2022525704 A5 JP 2022525704A5 JP 2022504337 A JP2022504337 A JP 2022504337A JP 2022504337 A JP2022504337 A JP 2022504337A JP 2022525704 A5 JP2022525704 A5 JP 2022525704A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- linker
- payload
- residue
- payload conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024186222A JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163810 | 2019-03-19 | ||
| EP19163810.5 | 2019-03-19 | ||
| PCT/EP2020/057697 WO2020188061A1 (en) | 2019-03-19 | 2020-03-19 | Transglutaminase conjugation method with a glycine based linker |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186222A Division JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525704A JP2022525704A (ja) | 2022-05-18 |
| JP2022525704A5 true JP2022525704A5 (enExample) | 2023-03-01 |
| JP7629902B2 JP7629902B2 (ja) | 2025-02-14 |
Family
ID=65903991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Active JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| JP2024186222A Pending JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024186222A Pending JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220133904A1 (enExample) |
| EP (1) | EP3941526A1 (enExample) |
| JP (2) | JP7629902B2 (enExample) |
| KR (1) | KR20220144753A (enExample) |
| CN (1) | CN113613679A (enExample) |
| AU (1) | AU2020243056A1 (enExample) |
| CA (1) | CA3128571A1 (enExample) |
| WO (1) | WO2020188061A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| JP7590354B2 (ja) * | 2019-06-10 | 2024-11-26 | ストロ バイオファーマ インコーポレーテッド | 免疫調節物質抗体薬物コンジュゲートおよびその使用 |
| EP4096717B1 (en) | 2020-01-31 | 2024-12-11 | Innate Pharma | Treatment of cancer |
| US20230095053A1 (en) * | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| KR20230069211A (ko) * | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| KR20230096052A (ko) * | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
| CN116801910A (zh) * | 2020-10-25 | 2023-09-22 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的手段和方法 |
| MX2023005873A (es) | 2020-11-25 | 2023-06-05 | Innate Pharma | Tratamiento del cancer. |
| KR20230142455A (ko) * | 2020-11-30 | 2023-10-11 | 앤비션 에스.알.엘. | 항체 단편으로 수식되고 세포독성 물질이 탑재된 다중특이인간 알부민 나노입자 |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| WO2023281480A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| EP4366781A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| JP2025505835A (ja) * | 2022-02-22 | 2025-02-28 | アーデーセー セラピューティクス ソシエテ アノニム | トリミングされたｎ－グリカンを含むｆｃ領域でのトランスグルタミナーゼを伴うコンジュゲーション方法 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| US20250179210A1 (en) | 2022-03-09 | 2025-06-05 | Merck Patent Gmbh | Anti-ceacam5 antibodies and conjugates and uses thereof |
| JP2025517476A (ja) | 2022-05-25 | 2025-06-05 | イナート・ファルマ・ソシエテ・アノニム | ネクチン－４結合剤 |
| EP4568997A1 (en) | 2022-08-08 | 2025-06-18 | ATB Therapeutics | Humanized antibodies against cd79b |
| CN115814111B (zh) * | 2022-12-05 | 2025-03-28 | 复旦大学附属中山医院 | 一种近红外荧光adc免疫制剂及其制备方法与应用 |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| CN116077676B (zh) * | 2023-02-03 | 2025-09-12 | 南京大学 | 蛋白质靶向降解嵌合体及其制备方法和应用 |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2025192692A1 (ja) * | 2024-03-14 | 2025-09-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2026008881A1 (en) | 2024-07-05 | 2026-01-08 | Synaffix B.V. | Extracellular vesicles comprising biomolecule-conjugates |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| AU2008215422B2 (en) | 2007-02-15 | 2011-07-14 | Ajinomoto Co., Inc. | Transglutaminase having disulfide bond introduced therein |
| US20100087371A1 (en) | 2007-02-22 | 2010-04-08 | Sean Hu | Transglutaminase Variants with Improved Specificity |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| WO2015015448A2 (en) | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| PT3134127T (pt) * | 2014-04-25 | 2020-04-09 | Rinat Neuroscience Corp | Conjugados de anticorpo-fármaco com alta carga de fármaco |
| WO2015191883A1 (en) * | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| CN107257802B (zh) | 2014-12-19 | 2021-11-23 | 豪夫迈·罗氏有限公司 | 转谷氨酰胺酶底物的鉴别及其用途 |
| WO2016100735A1 (en) | 2014-12-19 | 2016-06-23 | Roche Nimblegen, Inc. | Microbial transglutaminases, substrates therefor and methods for the use thereof |
| EP3256166A1 (en) * | 2015-02-09 | 2017-12-20 | NBE Therapeutics AG | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| JP2018510864A (ja) | 2015-03-10 | 2018-04-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 |
| ES2855998T3 (es) | 2015-08-07 | 2021-09-27 | Merck Patent Gmbh | Etiqueta transglutamina para bioconjugación específica de sitio eficiente |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
-
2020
- 2020-03-19 CA CA3128571A patent/CA3128571A1/en active Pending
- 2020-03-19 WO PCT/EP2020/057697 patent/WO2020188061A1/en not_active Ceased
- 2020-03-19 US US17/435,356 patent/US20220133904A1/en active Pending
- 2020-03-19 CN CN202080022652.9A patent/CN113613679A/zh active Pending
- 2020-03-19 EP EP20711197.2A patent/EP3941526A1/en active Pending
- 2020-03-19 AU AU2020243056A patent/AU2020243056A1/en active Pending
- 2020-03-19 JP JP2022504337A patent/JP7629902B2/ja active Active
- 2020-03-19 KR KR1020217033833A patent/KR20220144753A/ko active Pending
-
2024
- 2024-10-22 JP JP2024186222A patent/JP2025016545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525704A5 (enExample) | ||
| JP2025016545A5 (enExample) | ||
| JP2020534030A5 (enExample) | ||
| JP7629902B2 (ja) | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 | |
| JP2024081670A (ja) | トランスグルタミナーゼコンジュゲーション方法およびリンカー | |
| JP7244987B2 (ja) | 多剤抗体薬物コンジュゲート | |
| JP6310033B2 (ja) | 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法 | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| CN106456794B (zh) | 接头药物与抗体的位点特异性缀合以及所得adc | |
| KR20160120777A (ko) | 친수성 항체-약물 컨쥬게이트 | |
| JP2020528069A (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| JP2022547434A (ja) | 標的化デンドリマー複合体 | |
| CN112189020A (zh) | 包含微管蛋白破坏剂的抗体药物缀合物用于治疗实体瘤的用途 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| BR112020010937A2 (pt) | anticorpos anti-liv1 humanizados para o tratamento de câncer de mama | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2008515889A5 (enExample) | ||
| JP2023546493A (ja) | 抗体－リンカーコンジュゲートを生成するための手段および方法 | |
| CN111295201A (zh) | 抗egfr抗体药物结合物（adc）和其用途 | |
| TW201836647A (zh) | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 | |
| JP2024539989A (ja) | 抗体－リンカーコンジュゲートを生成する方法 | |
| CN109414509B (zh) | 使用双特异性抗体的抗体药物偶联物平台 | |
| JP2023542910A5 (enExample) | ||
| NZ779213B2 (en) | Transglutaminase conjugation method with a glycine based linker | |
| CA3149274A1 (en) | Immune tolerant elastin-like recombinant peptides and methods of use |